Form 4: Amicus Therapeutics CEO Disposes Shares for Tax

Amicus Therapeutics' President and CEO, Bradley L. Campbell, reported the disposition of 108,602 common shares at $14.25 per share, retaining over 1 million shares.

Summary

• Bradley L. Campbell, President and CEO of Amicus Therapeutics, disposed of 108,602 shares of common stock.
• The transaction occurred on December 26, 2025, at a price of $14.25 per share.
• The transaction code 'F' indicates shares were withheld for tax purposes upon the vesting of restricted stock or exercise of options.
• Following this transaction, Campbell directly beneficially owns 1,021,180 shares of Amicus Therapeutics common stock.

Sentiment

Score: 6

Explanation: The disposition of shares by the President and CEO is for tax withholding purposes (Transaction Code 'F'), which is a routine event upon vesting of equity awards. The executive retains a significant beneficial ownership of over 1 million shares, indicating continued alignment with the company's performance.

Positives

• The CEO retains a substantial beneficial ownership of 1,021,180 shares, indicating continued alignment with shareholder interests.

Negatives

• Disposition of shares by a key executive, even for tax purposes, can sometimes be perceived negatively by the market, though the 'F' code mitigates this.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

This filing is a standard insider transaction report and does not provide information related to broader industry trends or competitors.

Stakeholder Impact

• Shareholders: May interpret the disposition as a routine tax-related event, especially given the 'F' transaction code, rather than a signal of reduced confidence. The large remaining holding supports continued alignment.

Key Dates

Recommendation

The reported transaction is a routine disposition of shares for tax withholding purposes (Code F) by the President and CEO. This is not a discretionary sale and does not necessarily signal a change in management's outlook. The executive retains a substantial stake in the company, maintaining alignment with shareholder interests. Therefore, based solely on this Form 4, a 'hold' recommendation is appropriate as it provides no new fundamental information to alter an existing investment thesis.

Keywords

Amicus Therapeutics, FOLD, Bradley L. Campbell, insider trading, Form 4, common stock, CEO, share disposition, executive compensation